Levitt and colleagues revealed that Src was responsible for controlling urothelial cancer cell survival in vitro and that by blocking the effects of Src with dasatinib, the viability of these cancer cells was dramatically suppressed [38]. The gene discussed is SRC; the disease is cancer.